Investors

Phraxis is developing devices for surgeons and interventionalists to enable physicians to effectively manage their dialysis patients. 

Hemodialysis is a life-saving treatment for end stage renal disease (ESRD). Over 400,000 patients receive dialysis with an annual incidence of 100,000 new patients each year. The most serious problem facing Nephrologists who manage ESRD patients is vascular access so the blood can be withdrawn, dialyzed and returned to the patient three times per week. Currently used access methods are subject to failure, thrombosis and infection. 

The Phraxis InterGraft is a single use, implantable device that is delivered using conventional interventional tools. The device facilitates implantation of a standard synthetic vascular graft by eliminating the need to suture the venous anastomosis and potentially reduce the number of complications that arise due to stenosis and thrombosis at the venous anastomotic site.

If you should have any questions feel free to contact Phraxis, Inc.